Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Kimer Med, innovative New Zealand biotech start-up, signs contract with Battelle Memorial Institute to pioneer antiviral drug advances | ||
By: PR Newswire Association LLC. - 07 Mar 2024 | Back to overview list |
|
Download high resolution images here: www.kimermed.co.nz/media NELSON, New Zealand, March 7, 2024 /PRNewswire/ -- Kimer Med, a New Zealand-based biotech start-up, today announced it has signed a contract valued at up to USD$750,000 (NZD$1.3 million) with Battelle, the world's largest independent, nonprofit research and development organisation. The 12 month contract is funded by the United States government through the Defense Threat Reduction Agency (DTRA), and will fall into Battelle's Accelerated Therapeutics for Combating Acute Viral Epidemics programme. The contract is focused on the discovery and development of new antiviral drug candidates for the treatment of alphaviruses. Spread mostly by infected ticks and mosquitoes, alphaviruses cause significant human and animal disease. Infections that result in encephalitis - inflammation and swelling of the brain - are often fatal and can cause ongoing neurological problems. There is currently no effective antiviral treatment for alphavirus infection. "Approved antiviral drugs are currently available for only 11 out of more than 200 viruses that cause widespread sickness, suffering and death in humans," said Kimer Med's CEO, Rick Kiessig. "Our mission is to change that. We're developing a family of broad-spectrum antivirals capable of treating many of these infections." "This contract is an important milestone for Kimer Med, as it provides another opportunity to prove the capability of our platform for rapid, broad-spectrum antiviral development," said Kiessig. Since the company's launch in 2020, Kimer Med has developed antivirals that have shown in vitro efficacy against 11 different viruses, including the priority viruses Dengue (all four serotypes) and Zika. Their technology holds significant promise to deliver vital broad-spectrum antiviral treatments with a range of applications, including:
"With broad-spectrum antivirals, we have within our grasp the potential to revolutionise the treatment and prevention of viral infections in the way that penicillin did for bacterial infections. We're looking forward to working with such a highly-regarded and well-resourced organisation as Battelle to advance antiviral drug candidates that will be able to treat these alphaviruses, and hopefully a range of other viruses as well," said Kiessig. About Battelle About Kimer Med
View original content:https://www.prnewswire.com/news-releases/kimer-med-innovative-new-zealand-biotech-start-up-signs-contract-with-battelle-memorial-institute-to-pioneer-antiviral-drug-advances-302083553.html SOURCE Kimer Med |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |